Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners By: Veracyte, Inc. via Business Wire March 15, 2023 at 16:15 PM EDT Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. “Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs,” said Corinne Danan, general manager of Veracyte’s Biopharma business unit. “The abstracts accepted for presentation at AACR 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to continually enhancing and expanding the services available to these partners.” Following are details of the Veracyte abstracts that will be shared during poster sessions at the AACR Annual Meeting 2023: Title: Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex®, a sequential chromogenic multiplex assay Presenter: Jacques Fieschi, Ph.D., Veracyte Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET Location: Poster Section 4 Poster #: 14 Abstract #: 4624 Title: Veracyte Biopharma Atlas for colorectal cancer: combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture. Presenter: Florence Monville, Ph.D., Research Discovery, Veracyte Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET Location: Poster Section 37 Poster #: 26 Abstract #: 5476 Title: Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma Presenter: Régis Perbost, Ph.D., Veracyte and Mike Mattie, Ph.D., Kite a Gilead company Date/Time: Wednesday, April 19, 9:00 a.m.-12:30 p.m. ET Location: Poster Section 4 Poster #: 21 Abstract #: 5879 Veracyte will also host a Spotlight Theater at AACR 2023, highlighting how insights from the company’s multi-omics offerings and analytical capabilities can help biopharma partners more confidently advance oncology drug development programs. Title: Leveraging multi-omics insights to advance drug development programs Speakers: Corinne Danan, General Manager, Biopharma Services, Veracyte Jacques Fieschi, Ph.D., Research Discovery, Veracyte Jérôme Galon, Ph.D., Scientific Executive Director, Veracyte, and Research Director, Inserm Date/Time: Sunday, April 16, 3:30-4:30 p.m. ET Location: Exhibit Hall, Spotlight Theater About Veracyte’s Biopharma Offerings Veracyte collaborates with biopharma partners to provide novel insights, expertise and capabilities that empower partners to confidently advance every step of their oncology drug development programs. With an array of offerings that include the Veracyte Biopharma Atlas, Brightplex and Decipher GRID Real World Data (RWD), Veracyte helps address each partner’s unique oncology drug development needs, including therapeutics and diagnostic development, clinical development insights and decisions, clinical trial patient selection, and clinical trial management. For more information, please visit https://io.veracyte.com/. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q filed for the three months ended December 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. Veracyte, the Veracyte logo, Immunosign, Brightplex and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005836/en/Contacts Investors: Shayla Gorman Director, Investor Relations investors@veracyte.com 619-393-1545 Media: Tracy Morris Vice President of Global Corporate Communications tracy.morris@veracyte.com 650-380-4413 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners By: Veracyte, Inc. via Business Wire March 15, 2023 at 16:15 PM EDT Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. “Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs,” said Corinne Danan, general manager of Veracyte’s Biopharma business unit. “The abstracts accepted for presentation at AACR 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to continually enhancing and expanding the services available to these partners.” Following are details of the Veracyte abstracts that will be shared during poster sessions at the AACR Annual Meeting 2023: Title: Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex®, a sequential chromogenic multiplex assay Presenter: Jacques Fieschi, Ph.D., Veracyte Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET Location: Poster Section 4 Poster #: 14 Abstract #: 4624 Title: Veracyte Biopharma Atlas for colorectal cancer: combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture. Presenter: Florence Monville, Ph.D., Research Discovery, Veracyte Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET Location: Poster Section 37 Poster #: 26 Abstract #: 5476 Title: Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma Presenter: Régis Perbost, Ph.D., Veracyte and Mike Mattie, Ph.D., Kite a Gilead company Date/Time: Wednesday, April 19, 9:00 a.m.-12:30 p.m. ET Location: Poster Section 4 Poster #: 21 Abstract #: 5879 Veracyte will also host a Spotlight Theater at AACR 2023, highlighting how insights from the company’s multi-omics offerings and analytical capabilities can help biopharma partners more confidently advance oncology drug development programs. Title: Leveraging multi-omics insights to advance drug development programs Speakers: Corinne Danan, General Manager, Biopharma Services, Veracyte Jacques Fieschi, Ph.D., Research Discovery, Veracyte Jérôme Galon, Ph.D., Scientific Executive Director, Veracyte, and Research Director, Inserm Date/Time: Sunday, April 16, 3:30-4:30 p.m. ET Location: Exhibit Hall, Spotlight Theater About Veracyte’s Biopharma Offerings Veracyte collaborates with biopharma partners to provide novel insights, expertise and capabilities that empower partners to confidently advance every step of their oncology drug development programs. With an array of offerings that include the Veracyte Biopharma Atlas, Brightplex and Decipher GRID Real World Data (RWD), Veracyte helps address each partner’s unique oncology drug development needs, including therapeutics and diagnostic development, clinical development insights and decisions, clinical trial patient selection, and clinical trial management. For more information, please visit https://io.veracyte.com/. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q filed for the three months ended December 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. Veracyte, the Veracyte logo, Immunosign, Brightplex and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005836/en/Contacts Investors: Shayla Gorman Director, Investor Relations investors@veracyte.com 619-393-1545 Media: Tracy Morris Vice President of Global Corporate Communications tracy.morris@veracyte.com 650-380-4413
Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. “Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs,” said Corinne Danan, general manager of Veracyte’s Biopharma business unit. “The abstracts accepted for presentation at AACR 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to continually enhancing and expanding the services available to these partners.” Following are details of the Veracyte abstracts that will be shared during poster sessions at the AACR Annual Meeting 2023: Title: Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex®, a sequential chromogenic multiplex assay Presenter: Jacques Fieschi, Ph.D., Veracyte Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET Location: Poster Section 4 Poster #: 14 Abstract #: 4624 Title: Veracyte Biopharma Atlas for colorectal cancer: combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture. Presenter: Florence Monville, Ph.D., Research Discovery, Veracyte Date/Time: Tuesday, April 18, 1:30-5:00 p.m. ET Location: Poster Section 37 Poster #: 26 Abstract #: 5476 Title: Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma Presenter: Régis Perbost, Ph.D., Veracyte and Mike Mattie, Ph.D., Kite a Gilead company Date/Time: Wednesday, April 19, 9:00 a.m.-12:30 p.m. ET Location: Poster Section 4 Poster #: 21 Abstract #: 5879 Veracyte will also host a Spotlight Theater at AACR 2023, highlighting how insights from the company’s multi-omics offerings and analytical capabilities can help biopharma partners more confidently advance oncology drug development programs. Title: Leveraging multi-omics insights to advance drug development programs Speakers: Corinne Danan, General Manager, Biopharma Services, Veracyte Jacques Fieschi, Ph.D., Research Discovery, Veracyte Jérôme Galon, Ph.D., Scientific Executive Director, Veracyte, and Research Director, Inserm Date/Time: Sunday, April 16, 3:30-4:30 p.m. ET Location: Exhibit Hall, Spotlight Theater About Veracyte’s Biopharma Offerings Veracyte collaborates with biopharma partners to provide novel insights, expertise and capabilities that empower partners to confidently advance every step of their oncology drug development programs. With an array of offerings that include the Veracyte Biopharma Atlas, Brightplex and Decipher GRID Real World Data (RWD), Veracyte helps address each partner’s unique oncology drug development needs, including therapeutics and diagnostic development, clinical development insights and decisions, clinical trial patient selection, and clinical trial management. For more information, please visit https://io.veracyte.com/. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q filed for the three months ended December 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. Veracyte, the Veracyte logo, Immunosign, Brightplex and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005836/en/
Investors: Shayla Gorman Director, Investor Relations investors@veracyte.com 619-393-1545 Media: Tracy Morris Vice President of Global Corporate Communications tracy.morris@veracyte.com 650-380-4413
